Seroprevalencia de anticuerpos IGG contra SARS-COV-2 en personal vacunado del hospital de especialidades Carlos Andrade Marín en el periodo julio – diciembre 2021

Abstract

In 2019, the outbreak of pneumonia of unknown etiology in the city of Wuhan, Hubei province, China, and its accelerated spread not only in the epicenter city but also around the world, alarmed health systems due to several factors such as lack of knowledge of the transmission routes, how to treat infected individuals, how to recognize the signs and symptoms of the disease, making it a global public health problem only two months after the first reported cases. As it is an emerging disease, there is no specific treatment so far, so the exposed population has a high probability of infection and development of weak, moderate or severe symptomatology. Reports on the effectiveness of vaccines against this virus have been very encouraging, taking this preventive measure as the best method to avoid serious consequences. The vaccination process that began in the last weeks of 2020 worldwide and in Ecuador at the beginning of the 2021, the inoculated population is growing rapidly and the level of protection it provides is causing a decrease in mortality, in the Hospital de Especialidades Carlos Andrade Marín vaccination of the staff working in this health center began in March reaching most of the staff, so far has managed to immunize more than 90% of the servers. Establishing the seroprevalence of antibodies against SARS CoV-2 in vaccinated personnel, allows determine the immunity generated over this population. Expected results: the presence of IgG antibodies against SARSCoV- 2 in all HECAM vaccinated health personnel, regardless of both the type of vaccine inoculated, and the time of inoculation. It is expected that there will be a significant difference in the antibody titer between health personnel who complied with the vaccination schedule and those who already had the disease (COVID-19) and were vaccinated.